Multigene-expression tests for breast cancer

Languages

Service navigation

Search

Contact information

Multigene-expression tests for breast cancer

Multigene-expression tests for breast cancer are covered by compulsory health insurance subject to certain conditions. Multigene-expression tests are to help decide whether to proceed with chemotherapy following a breast cancer operation. An HTA report has been commissioned to evaluate the compulsory reimbursement of multigene-expression tests for early-stage breast cancer in order to examine the clinical effectiveness, safety, cost-effectiveness and budget impact as well as the ethical, legal, societal  and organizational aspects.

Documents

HTA protocol (PDF, 620 kB, 17.05.2024)

Stakeholder feedback on the HTA protocol (PDF, 242 kB, 17.05.2024)

< back to HTA projects

Last modification 28.05.2024

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/multigeneexpressiontests.html